• bioAffinity Technologies published a clinical review outlining a framework for pulmonary nodule risk stratification using its CyPath Lung test.
• Analysis flags rising demand as lung screening expands, incidental nodules increase, AI detection grows, and more survivors require long-term surveillance.
• Framework targets adoption in primary care, pulmonology nodule programs, interventional pulmonology, and oncology surveillance workflows.
• CyPath Lung positioned as a noninvasive sputum-based tool to complement imaging and predictive models, aiming to reduce unnecessary invasive procedures.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607270808BIZWIRE_USPR_____20260727_BW737775) on July 27, 2026, and is solely responsible for the information contained therein.